Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance PathwaysMirjam C. Boelens, Andy J. Minn, Diana J. Azzam et al.|Cell|2014Cited by 798
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategySeth A. Wander, Joyce M. Slingerland|Journal of Clinical Investigation|2011Cited by 417
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2Dekuang Zhao, Joyce M. Slingerland, Chendong Pan et al.|Oncogene|2014Cited by 264
DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast CancerHetakshi Kurani, Joyce M. Slingerland|Clinical Cancer Research|2022Cited by 71
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapySeth A. Wander, Joyce M. Slingerland, Andy J. Minn et al.|Breast Cancer Research and Treatment|2013Cited by 58